On July 7, 2025, Novo Nordisk launched its weight-loss drug Wegovy in India, entering a market where demand for obesity treatments is rapidly increasing. This strategic entry positions the company in a country grappling with a rising incidence of obesity and diabetes.
Since its late-June launch, Novo Nordisk has sold almost 1,800 units of Wegovy in India, according to research firm Pharmarack. This initial uptake indicates a positive reception in a market valued at $73 million, which has grown fivefold since 2021.
While Eli Lilly's Mounjaro also competes in India, Wegovy's active ingredient, semaglutide, already holds a two-thirds share in the Indian market through oral versions for diabetes. This market entry is crucial for Novo Nordisk to capitalize on the vast, underserved patient population in India.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.